Krystal Biotech filings document formal disclosures for a commercial-stage biotechnology company developing and commercializing genetic medicines. Recent 8-K reports furnish quarterly and annual financial results, VYJUVEK net product revenue updates, Regulation FD clinical materials, FDA-related program updates, and commercial launch information for VYJUVEK in Japan.
The company's proxy materials disclose board and shareholder-vote matters, executive compensation, equity awards, ownership information, and governance practices. Together, the filings record how Krystal reports operating performance, capital resources, pipeline and regulatory disclosures, and public-company governance for its HSV-1-based gene therapy platform.
Krystal Biotech, Inc. reported third-quarter 2026 net product revenue of $127.3 million, up 30% from $97.8 million a year earlier, and net income of $63.1 million versus $79.4 million. For the first nine months, product revenue was $362.9 million versus $282.0 million, while net income was $173.8 million versus $153.4 million. Gross margin was 94%, and cash, cash equivalents and investments totaled $1.2 billion as of September 30, 2026.
The board authorized repurchases of up to $400 million of common stock; the program has no expiration date and does not require purchases. Krystal expects opportunistic repurchases over the next two years, and may modify, suspend or discontinue the program. FY 2026 non-GAAP combined R&D and SG&A expense guidance is $155.0 million to $165.0 million, excluding stock-based compensation. In a three-patient KB113 pilot, more than 80% of assessed basal cell carcinoma lesions showed investigator-assessed clinical regression. KB801 enrollment was slower than anticipated, with top-line results now expected in 2027; Krystal expects an Italy VYJUVEK launch in early 2027.
Krystal Biotech, Inc. reported third-quarter 2026 product revenue, net, of $127.3 million, up 30% from $97.8 million a year earlier, with the increase primarily driven by VYJUVEK sales following launches in Europe and Japan. Net income was $63.1 million, versus $79.4 million; the comparison includes a $31.4 million income tax benefit in 2025 and a $17.1 million income tax expense in 2026. For the first nine months, product revenue was $362.9 million versus $282.0 million, and net income was $173.8 million versus $153.4 million.
Cash, cash equivalents and short-term investments totaled approximately $911.9 million as of September 30, 2026; management expects these funds to support planned operations for at least 12 months from the report date. Net cash provided by operating activities was $246.4 million, compared with $123.4 million a year earlier. In October, the board authorized repurchases of up to $400 million of common stock; the program has no expiration date and does not obligate the company to buy a particular amount.
Krystal expects the last patient visit in its KB803 IOLITE study in February 2027, with top-line results shortly thereafter. Enrollment in the KB801 EMERALD-1 study is ongoing, with enrollment completion and top-line results expected in 2027.
Krystal Biotech, Inc. (KRYS) is the issuer of the shares for which Vanguard Portfolio Management reported beneficial ownership of 1,312,431 shares, or 4.43%, as of September 30, 2026. Vanguard reported sole dispositive power over 1,312,431 shares and sole voting power over 25,577 shares; shared voting and dispositive power were both zero. The disclosure attributes the reported holdings to Vanguard Portfolio Management LLC and specified affiliates or business divisions. It states that no other person's interest in the reported securities exceeds 5%.
Krystal Biotech, Inc. (KRYS) is the issuer of the shares in BlackRock, Inc.’s fifth amended beneficial-ownership report. BlackRock reported 3,427,645 common shares, or 11.6% of the class, as of September 30, 2026. BlackRock reported sole voting power over 3,358,055 shares and sole dispositive power over 3,427,645 shares, with no shared voting or dispositive power.
Krystal Biotech, Inc. (KRYS) reported preliminary KB113 results from a Gorlin syndrome pilot involving three adult patients. At the final assessment, 69 of 83 landmark lesions (83.1%) had some clinical regression; 42 of 83 (50.6%) regressed by more than 50%, and 8 of 83 (9.6%) by at least 90%. One lesion per patient with at least 90% regression was biopsied, and all three showed histologically confirmed complete response.
The poster reports that all 22 adverse events were mild or moderate, transient, and resolved during the study; no serious adverse events were reported. Krystal said it had initiated discussions with the FDA about advanced clinical development and would update its plans following alignment with the agency. The data were from an unaudited snapshot dated September 17, 2026. Each patient received six doses over 14 weeks, with the first two doses two weeks apart and subsequent doses every three weeks. Results were presented at the PeDRA conference held October 15–17, 2026.
Krystal Biotech, Inc. (KRYS) reported that director Dino A. Rossi received new equity awards on September 14, 2026. He was granted options to purchase 1,187 shares of common stock at an exercise price of $340.03 per share, expiring on September 13, 2036, which vest in full on September 14, 2027, subject to continued service on the Board and earlier vesting conditions under the company's Non-Employee Director Compensation Policy. He also received 471 restricted stock units, each representing a contingent right to one share of common stock, which vest in full on September 14, 2027 under the same service and policy conditions.
Krystal Biotech, Inc. (symbol: KRYS) is the issuer of record for a Form 4 filing submitted to the SEC. Sutherland Everett Rand reported acquisition or exercise transactions in this Form 4 filing.
Krystal Biotech, Inc. (KRYS) reported that director Everett Rand Sutherland received equity awards on September 14, 2026. He was granted 1,187 stock options to buy common stock at $340.03 per share, vesting in full on September 14, 2027, and 471 restricted stock units, also vesting in full on that date, in each case subject to continued Board service and earlier vesting conditions under the company’s Non-Employee Director Compensation Policy.
Krystal Biotech, Inc. (symbol: KRYS) is the issuer of record for a Form 4 filing submitted to the SEC. Mazzacco Catherine reported acquisition or exercise transactions in this Form 4 filing.
Krystal Biotech, Inc. (KRYS) reported that director Catherine Mazzacco received equity awards on September 14, 2026. She was granted 1,187 stock options to buy common stock at $340.03 per share, expiring on September 13, 2036, and 471 restricted stock units. Both awards vest in full on September 14, 2027, subject to her continued service on the board and potential earlier vesting under the company’s Non-Employee Director Compensation Policy. No Rule 10b5-1 trading plan is reported for these awards.
Krystal Biotech, Inc. (symbol: KRYS) is the issuer of record for a Form 4 filing submitted to the SEC. Mason Christopher reported acquisition or exercise transactions in this Form 4 filing.
Krystal Biotech, Inc. director Christopher Mason received equity awards in the form of stock options and restricted stock units. On September 14, 2026 he was granted 1,187 stock options to buy common stock at $340.03 per share, expiring September 13, 2036, and 471 restricted stock units, each representing one share of common stock. Both the options and RSUs vest in full on September 14, 2027, subject to his continued service on the Board of Directors and potential earlier vesting under the company’s Non-Employee Director Compensation Policy. No Rule 10b5-1 trading plan is reported.
Krystal Biotech, Inc. (KRYS) reported that director Daniel Janney received equity awards on September 14, 2026. He was granted 1,187 stock options with an exercise price of $340.03 per share, expiring on September 13, 2036, and 471 restricted stock units. Both the options and RSUs vest in full on September 14, 2027, subject to Mr. Janney’s continued service on the board and earlier vesting conditions described in the company’s Non-Employee Director Compensation Policy. No Rule 10b5-1 trading plan is reported.